226 related articles for article (PubMed ID: 35527168)
1. IL-6 and its role in IgA nephropathy development.
Groza Y; Jemelkova J; Kafkova LR; Maly P; Raska M
Cytokine Growth Factor Rev; 2022 Aug; 66():1-14. PubMed ID: 35527168
[TBL] [Abstract][Full Text] [Related]
2. IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells.
Novak J; Raskova Kafkova L; Suzuki H; Tomana M; Matousovic K; Brown R; Hall S; Sanders JT; Eison TM; Moldoveanu Z; Novak L; Novak Z; Mayne R; Julian BA; Mestecky J; Wyatt RJ
Nephrol Dial Transplant; 2011 Nov; 26(11):3451-7. PubMed ID: 21828345
[TBL] [Abstract][Full Text] [Related]
3. Cellular signaling and production of galactose-deficient IgA1 in IgA nephropathy, an autoimmune disease.
Reily C; Ueda H; Huang ZQ; Mestecky J; Julian BA; Willey CD; Novak J
J Immunol Res; 2014; 2014():197548. PubMed ID: 25152896
[TBL] [Abstract][Full Text] [Related]
4. Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system.
Novak J; Moldoveanu Z; Julian BA; Raska M; Wyatt RJ; Suzuki Y; Tomino Y; Gharavi AG; Mestecky J; Suzuki H
Adv Otorhinolaryngol; 2011; 72():60-3. PubMed ID: 21865691
[TBL] [Abstract][Full Text] [Related]
5. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.
Makita Y; Suzuki H; Kano T; Takahata A; Julian BA; Novak J; Suzuki Y
Kidney Int; 2020 Feb; 97(2):340-349. PubMed ID: 31748116
[TBL] [Abstract][Full Text] [Related]
6. Sialylation of IgG inhibits the formation of galactose-deficient IgA1-containing immune complexes and protects mesangial cells from injury in IgA nephropathy.
Liu Y; Li H; Yu H; Wang F; Jia J; Yan T
BMC Nephrol; 2022 Jan; 23(1):25. PubMed ID: 35016642
[TBL] [Abstract][Full Text] [Related]
7. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy.
Moura IC; Arcos-Fajardo M; Gdoura A; Leroy V; Sadaka C; Mahlaoui N; Lepelletier Y; Vrtovsnik F; Haddad E; Benhamou M; Monteiro RC
J Am Soc Nephrol; 2005 Sep; 16(9):2667-76. PubMed ID: 15987753
[TBL] [Abstract][Full Text] [Related]
8. Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy.
Reily C; Moldoveanu Z; Pramparo T; Hall S; Huang ZQ; Rice T; Novak L; Komers R; Jenkinson CP; Novak J
Am J Physiol Renal Physiol; 2024 May; 326(5):F862-F875. PubMed ID: 38511222
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.
Zhao YF; Zhu L; Liu LJ; Shi SF; Lv JC; Zhang H
BMC Nephrol; 2017 Sep; 18(1):301. PubMed ID: 28969604
[TBL] [Abstract][Full Text] [Related]
10. Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.
Zachova K; Jemelkova J; Kosztyu P; Ohyama Y; Takahashi K; Zadrazil J; Orsag J; Matousovic K; Galuszkova D; Petejova N; Mestecky J; Raska M
J Am Soc Nephrol; 2022 May; 33(5):908-917. PubMed ID: 35115327
[TBL] [Abstract][Full Text] [Related]
11. Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy.
Cambier A; Gleeson PJ; Abbad L; Canesi F; da Silva J; Bex-Coudrat J; Deschênes G; Boyer O; Rabant M; Ulinski T; Hogan J; Peuchmaur M; Berthelot L; Monteiro RC
Kidney Int; 2022 Feb; 101(2):274-287. PubMed ID: 34756952
[TBL] [Abstract][Full Text] [Related]
12. Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1.
Ebefors K; Liu P; Lassén E; Elvin J; Candemark E; Levan K; Haraldsson B; Nyström J
BMC Nephrol; 2016 Apr; 17():40. PubMed ID: 27044423
[TBL] [Abstract][Full Text] [Related]
13. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells.
Novak J; Tomana M; Matousovic K; Brown R; Hall S; Novak L; Julian BA; Wyatt RJ; Mestecky J
Kidney Int; 2005 Feb; 67(2):504-13. PubMed ID: 15673298
[TBL] [Abstract][Full Text] [Related]
14. LPS/TLR4 Pathway Regulates IgA1 Secretion to Induce IgA Nephropathy.
He H; Shen M; Tang Y; Sun W; Xu X
Altern Ther Health Med; 2024 Jan; 30(1):419-425. PubMed ID: 37820669
[TBL] [Abstract][Full Text] [Related]
15. Glomerular galactose-deficient IgA1 expression analysis in pediatric patients with glomerular diseases.
Ishiko S; Horinouchi T; Fujimaru R; Shima Y; Kaito H; Tanaka R; Ishimori S; Kondo A; Nagai S; Aoto Y; Sakakibara N; Nagano C; Yamamura T; Yoshimura M; Nakanishi K; Fujimura J; Kamiyoshi N; Nagase H; Yoshikawa N; Iijima K; Nozu K
Sci Rep; 2020 Aug; 10(1):14026. PubMed ID: 32820208
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
Wada Y; Matsumoto K; Suzuki T; Saito T; Kanazawa N; Tachibana S; Iseri K; Sugiyama M; Iyoda M; Shibata T
PLoS One; 2018; 13(11):e0206865. PubMed ID: 30388165
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy.
Novak J; Barratt J; Julian BA; Renfrow MB
Semin Nephrol; 2018 Sep; 38(5):461-476. PubMed ID: 30177018
[TBL] [Abstract][Full Text] [Related]
18. Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glomerular endothelial cell injuries.
Makita Y; Suzuki H; Nakano D; Yanagawa H; Kano T; Novak J; Nishiyama A; Suzuki Y
Nephrol Dial Transplant; 2022 Aug; 37(9):1629-1636. PubMed ID: 35746884
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.
Zhang K; Li Q; Zhang Y; Shang W; Wei L; Li H; Gao S; Yan T; Jia J; Liu Y; Lin S
Kidney Blood Press Res; 2019; 44(5):1196-1206. PubMed ID: 31574506
[TBL] [Abstract][Full Text] [Related]
20. Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy.
Moldoveanu Z; Suzuki H; Reily C; Satake K; Novak L; Xu N; Huang ZQ; Knoppova B; Khan A; Hall S; Yanagawa H; Brown R; Winstead CJ; O'Quinn DB; Weinmann A; Gharavi AG; Kiryluk K; Julian BA; Weaver CT; Suzuki Y; Novak J
J Autoimmun; 2021 Mar; 118():102593. PubMed ID: 33508637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
